Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis

ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near

Thu, September 24, 2026 at 11:20 AM UTC 4 min read

Goldman Sachs has resumed coverage of Arrowhead Pharmaceuticals (ARWR) with a price target of $74, highlighting the upcoming clinical catalysts that could significantly impact the company's stock performance. This renewed attention from a major investment firm suggests confidence in ARWR's potential advancements in its pipeline, which could attract investor interest and drive share prices higher. Investors should monitor these developments closely as they may influence future valuation and market sentiment.

Read full article →

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress

Sat, September 19, 2026 at 12:02 AM UTC 3 min read

Arrowhead Pharmaceuticals recently highlighted promising dual-target RNA interference (RNAi) data and provided updates on the launch progress of its drug, Plozasiran. This development is significant for investors as it showcases the company's innovative approach to treating diseases and may enhance its competitive position in the biotech sector. Positive data and successful product launches could lead to increased investor confidence and potential revenue growth for Arrowhead.

Read full article →